These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
481 related items for PubMed ID: 20435246
1. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246 [Abstract] [Full Text] [Related]
3. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. DeRyke CA, Kuti JL, Nicolau DP. Pharmacotherapy; 2007 Mar; 27(3):333-42. PubMed ID: 17316145 [Abstract] [Full Text] [Related]
4. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Ann Pharmacother; 2009 Feb; 43(2):220-7. PubMed ID: 19193582 [Abstract] [Full Text] [Related]
6. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP. Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212 [Abstract] [Full Text] [Related]
9. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. Masterton RG, Kuti JL, Turner PJ, Nicolau DP. J Antimicrob Chemother; 2005 Jan; 55(1):71-7. PubMed ID: 15574471 [Abstract] [Full Text] [Related]
10. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region. Kiratisin P, Keel RA, Nicolau DP. Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484 [Abstract] [Full Text] [Related]
11. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002. Kiffer CR, Mendes C, Kuti JL, Nicolau DP. Diagn Microbiol Infect Dis; 2004 Jun; 49(2):109-16. PubMed ID: 15183860 [Abstract] [Full Text] [Related]
12. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, Nicolau DP. Int J Antimicrob Agents; 2007 Nov; 30(5):452-7. PubMed ID: 17646088 [Abstract] [Full Text] [Related]
13. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia. Villegas MV, Briceno DF, Ruiz SJ, Furtado GH, Nicolau DP. Braz J Infect Dis; 2011 Nov; 15(5):413-9. PubMed ID: 22230846 [Abstract] [Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital. Furtado GH, Cardinal L, Macedo RS, Silva JO, Medeiros EA, Kuti JL, Nicolau DP. Rev Soc Bras Med Trop; 2015 Nov; 48(5):539-45. PubMed ID: 26516962 [Abstract] [Full Text] [Related]
16. Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program. Koomanachai P, Crandon JL, Kuti JL, Nicolau DP. Int J Antimicrob Agents; 2009 Apr; 33(4):348-53. PubMed ID: 19091515 [Abstract] [Full Text] [Related]